Trial record 16 of 68 for:    arrhythmia OR atrial fibrillation OR ventricular fibrillation OR tachycardia OR bradycardia | Open Studies | NIH, U.S. Fed

Predictors of Anticoagulation Control on Warfarin Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by University of Pennsylvania.
Recruitment status was  Recruiting
Information provided by:
University of Pennsylvania Identifier:
First received: May 18, 2009
Last updated: December 1, 2009
Last verified: December 2009

The goal of this research study is to develop better dosing of anticoagulation medication in both Caucasian and African Americans through analysis of various genetic factors.

Atrial Fibrillation
Deep Vein Thrombosis
Heart Valve Replacement

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predictors of Anticoagulation Control on Warfarin Therapy

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Biospecimen Retention:   Samples With DNA

A one time blood sample will be collected for specific genetic testing and vitamin K assay

Estimated Enrollment: 1119
Study Start Date: June 2009
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Detailed Description:

This is a prospective cohort study among adult patients requiring warfarin therapy. Patients presenting for anticoagulation will be identified at the start of therapy and followed throughout their course until they reach maintenance dose. We will then develop a dosing equation for warfarin using patient, environmental and genetic factors.


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Study population will include all self-identified Caucasians and African Americans initiating warfarin therapy.


Inclusion Criteria:

  • All Caucasians and African Americans who are new to warfarin therapy

Exclusion Criteria:

  • Under 21 years of age
  • Non caucasian
  • Non african american
  • Have an abnormal INR before warfarin or heparin therapy
  • Unable to provide consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00905177

Contact: Luanne Bershaw, LPN,BA,CIP 215-573-9242

United States, Pennsylvania
Hospital of the University of Pennsylvania, Anticoagulation Management Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Luanne Bershaw, LPN,BA,CIP    215-573-9242   
Contact: Stephen E. Kimmel, M.D.    215-898-1740   
Principal Investigator: Stephen E. Kimmel, MD., MSCE.         
Philadelphia Veteran Affairs Medical Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Luanne Bershaw, LPN,BA,CIP    215-573-9242   
Principal Investigator: Stephen E. Kimmel, M.D.         
Sponsors and Collaborators
University of Pennsylvania
Principal Investigator: Stephen E. Kimmel, M.D. MS University of Pennsylvania
  More Information

No publications provided

Responsible Party: Steve Kimmel, M.D., MSce, University of Pennsylvania, School of Medicine Identifier: NCT00905177     History of Changes
Other Study ID Numbers: 700902
Study First Received: May 18, 2009
Last Updated: December 1, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pennsylvania:
Atrial Fibrillation
deep vein thrombosis

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Venous Thrombosis
Cardiovascular Diseases
Embolism and Thrombosis
Heart Diseases
Pathologic Processes
Vascular Diseases
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on August 27, 2015